Tanito Masaki
Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo 693-8501, Shimane, Japan.
J Pers Med. 2022 Jun 11;12(6):956. doi: 10.3390/jpm12060956.
To report the updated prescription trend of antiglaucoma medications, the dose-based prescription of a glaucoma medication in Japan in the fiscal year 2019 was aggregated by using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open data. Of the 100 most frequently prescribed topical medications for outpatients from out-hospital pharmacies, 32 glaucoma medications were identified. This year, 150.8 million ml of glaucoma medications prescribed accounted for 12.3% of the total prescription dose (1.3 billion ml). The dose was the largest with prostaglandin FP2α agonist (PGF2α), followed by the fixed-dose combination (FDC) of β-blocker and carbonic anhydrase inhibitor (β + CAI) and α2-agonist. Prescription doses peaked at 75−79 years old for all medication classes, except for prostaglandin EP2 agonist of that peaked 10 years younger age class than other medications. The prescription dose was larger in women (55.3%) than men (44.7%), single medication formulation (71.2%) than FDC (28.8%), and brand-name (85.2%) than generic (14.8%). By multivariate analysis, prescription doses were affected by roles of the sex (p = 0.0066) and brand-name or generic (p = 0.032), but not by single medication formulation or FDC (p = 0.67); age was the most remarkable parameter for the difference in prescription dose (p < 0.0001). Dose-based anti-glaucoma medication prescription was analyzed using the government-provided most recent database on a national scale. The results provide the up-to-date real-world glaucoma medication prescriptions where the country has the highest aging rate in the world.
为报告抗青光眼药物的最新处方趋势，利用日本医保理赔与特定健康检查国家数据库（NDB）开放数据，汇总了2019财年日本青光眼药物的基于剂量的处方情况。在从医院外药房开出的门诊患者最常用的100种局部用药中，确定了32种青光眼药物。今年，开出的青光眼药物为1.508亿毫升，占总处方剂量（13亿毫升）的12.3%。剂量最大的是前列腺素FP2α激动剂（PGF2α），其次是β受体阻滞剂与碳酸酐酶抑制剂的固定剂量复方制剂（β + CAI）和α2激动剂。除前列腺素EP2激动剂的处方剂量在比其他药物小10岁的年龄组达到峰值外，所有药物类别的处方剂量在75 - 79岁达到峰值。女性（55.3%）的处方剂量高于男性（44.7%），单一药物剂型（71.2%）高于固定剂量复方制剂（28.8%），品牌药（85.2%）高于非专利药（14.8%）。多因素分析显示，处方剂量受性别（p = 0.0066）和品牌药或非专利药（p = 0.032）的影响，但不受单一药物剂型或固定剂量复方制剂的影响（p = 0.67）；年龄是处方剂量差异最显著的参数（p < 0.0001）。利用政府提供的全国最新数据库对基于剂量的抗青光眼药物处方进行了分析。结果提供了这个世界上老龄化率最高国家的最新真实世界青光眼药物处方情况。
